Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 22, Issue 3, 2003, Pages 147-165

  Jafri, Nazia F ^a,b   Ma, Patrick C ^a,c,d   Maulik, Gautam ^a   Salgia, Ravi ^a,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

C Kit; C Met; Mechanisms of metastasis; Receptor tyrosine kinases; Signal transduction; Small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADRENAL METASTASIS; BRAIN METASTASIS; CANCER CELL; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; DOWNSTREAM PROCESSING; DRUG TARGETING; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 0041336958     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvPathToxOncol.v22.i3.10     Document Type: Review

References (76)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward, E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
2. Chute JP, Chen T, Feigal E, Simon R, Johnson BE, Twenty years of phase III trials for patients with extensive-stage small cell lung cancer: perceptible progress. J Clin Oncol 1999; 17:1794-1801.
3. Salgia R, Skarin AT. Lung cancer: from molecular biology to novel therapeutics. Hosp Physic 1996:12-32.
4. Turrisi A. Concurrent chemoradiotherapy for limited small-cell lung cancer. Oncology 1997; 11:31-37.
5. Shopland DR. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect 1995; 103:131-142.
6. Johnson BE. Management of small cell lung cancer. In: Matthay RA, editor. Clinics in Chest Medicine. Totowa, NJ: Humana, 2002.
7. Fong KM, Minna JD. Molecular biology of lung cancer, clinical implications. In: Matthay RA, editor. Clinics in Chest Medicine. Totowa, NJ: Humana, 2002.
8. Travis WD. Pathology of lung cancer. In: Matthay RA, editor. Clinics in Chest Medicine. Totowa, NJ: Humana, 2002.
9. Radinsky R, Aukerman SL, Fidler IJ. Implications of host-tumor interactions during metastasis. In: Oldham RK, editor. Principles of Cancer Biotherapy. The Netherlands, Kluwer, 1998.
10. Comoglio PM, Trusolino L. Invasive growth: from development to metastasis. J Clin Invest 2002; 109:857-862.
11. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002; 13:41-59.
12. Fidler IJ, Radinsky R. Genetic control of cancer metastasis (editorial). J Natl Cancer Inst 1990; 82:166-168.
13. Poste G. Experimental systems for analysis of the malignant phenotype. Cancer Metast Rev 1982; 1:141-199.
14. Liotta LA.Tumor invasion and metastases - role of the extracellular matrix. Rhoads Memorial Award Lecture. Cancer Res 1986; 46:1-7.
15. Liotta LA, Thorgeirsson UP, Garbisa S. Role of collagenases in tumor cell invasion. Cancer Metast Rev 1982; 1:277-288.
16. Matrisian LM. The matrix-degrading metalloproteinases. Bioassays 1992; 14:455-463.
17. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastases. Cancer Metast Rev 1990; 9:289-303.
18. Kramer RH, Gonzalez R, Nicolson GL. Metastatic tumor cells adhere preferentially to the extracellular matrix underlying vascular endothelial cells. Int J Cancer 1980; 26:639-645.
19. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197:893-895.
20. Luria SE, Delbruk M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943; 28:491-511.
21. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1998; 1:571-573.
22. th Edition. Philadelphia, PA: WB Saunders, 1928.
23. Sugarbaker EV. Patterns of metastasis in human malignancies. Cancer Biol Rev 1981; 2:235-278.
24. Giavazzi R, Campbell DE, Jessup JM, Cleary KR, Fidler IJ. Metastatic behavior of tumor cells from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res 1986; 46:1928-1933.
25. Laurent D, Durbec P, Gautherot E, Rouvier E, Rougnon G, Figarella-Branger D. A nude mice model of human rhabdomyosarcoma lung metastases for evaluating the role of polysialic acids in the metastatic process. Oncogene 2001; 20:997-1004.
26. Salgia R, Li J, Ewaniuk DS, Wang Y, Sattler M, Chen W, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, Griffin JD, Sugarbaker DJ. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene 1999; 18:67-77.
27. Rintoul RC, Sethi T. The role of extracellular matrix in small-cell lung cancer. Lancet Oncol 2001; 2:437-441.
28. Kuratomi Y, Nomizu M, Tanaka K, Ponce ML, Komivama S, Kleinman HK, Yamada Y. Laminin γ1 chain peptide C-16 (KAFDITYVRLKF), promotes migration, MMP-9 secretion, and pulmonary metastasis of B16-F10 melanoma cells. Br J Cancer 2002; 86:1169-1173.
29. 1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells. Cancer Res 2000; 60:457-466.
30. Palecek SP, Loftus JC, Ginsberg MH. Integrin ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 1997; 385:537-540.
31. Huttenlucher A, Ginsberg MH, Horwitz AS. Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand binding affinity. J Cell Biol 1996; 134:1551-1560.
32. Humphries MJ. Integrin activation: the link between ligand binding and signal transduction. Curr Opin Cell Biol 1996; 8:632-640.
33. Fenczik CA, Sethi T, Ramos JW. Complementation of dominant suppression implicates CD98 in integrin activation. Nature 1997; 390:81-85.
34. Sheski FD, Natarajan V, Pottratz ST. Tumor necrosis factor-α stimulates attachment of small cell lung carcinoma to endothelial cells. J Lab Clin Med 1999; 133:265-273.
35. Salgia R, Strauss GM. Molecular markers in nonsmall cell lung cancer. Up-To-Date: 1-21, 2002.
36. He C, He P, Liu LP, Zhu YS. Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells. J Cancer Res Clin Oncol 2001; 127:180.
37. Yoshino H, Endo Y, Watanabe Y, Sasaki T. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. Br J Cancer 1998; 78:833-839.
38. Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, Leco K, Chamberlain D, Shepherd FA. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small cell lung cancer. J Clin Oncol 1999; 17:1802-1808.
39. Ponton A, Coulombe B, Skup D. Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res 1991; 51:2138.
40. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2): a new member of the metalloproteinase inhibitor family. J Biol Chem 1989; 264:17374-17378.
41. Staskus PW, Masiarz FR, Pallanck LJ, Hawkes SP. The 21-kDa protein is a transformation-sensitive metalloproteinase inhibitor of chicken fibroblasts. J Biol Chem 1991; 266:449-454.
42. Li H, Fang W, Shi Z. Effects of TIMP-2 gene transfection on biological behaviors of a metastatic human lung carcinoma cell line. Zhonghua Yi Xue Za Zhi 1997; 77:652.
43. Ellis LM, Fidler IJ. Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, editors. The Molecular Basis of Cancer. Philadelphia PA, WB Saunders, 2001.
44. Jager R, List B, Knabbe C, Souttou B, Raulais D, Zeiler T, Wellstein A, Aigner A, Neubauer A, Zugmaier G. Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients. Br J Cancer 2002; 86:858-863.
45. Salgia R, Con D, Sattler M. Molecular and cellular biology of small cell lung cancer. Semin Oncol 2003; 35:57-71.
46. Wang W, Healv M, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R. Growth inhibition and modulation of kinase pathways of small cell lung cancer lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000; 19:3521-3528.
47. Arteaga CL, Khuri F, Krystal G, Sebti S. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Semin Oncol 2002; 29:15-26.
48. Park GH, Plummer HK, Krystal GW. Selective Sp1 binding is critical for maximal activity of the human c-kit promoter. Blood 1998; 92:4138-4149.
49. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20:1692-1703.
50. Krystal GW, DeBerry CS, Linnekin D, Litz J. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1. Cancer Res 1998; 58:4660-4666.
51. Lev S, Blechman JM, Givol D. Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit Rev Oncogen 1994; 5:141-168.
52. Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000; 6:3319-3326.
53. Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002; 62:6304-6311.
54. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18:217-242.
55. Zhang XF, Wang JF, Matczak E, Proper JA, Groopman JE. Janus kinase 2 is involved in stromal cell-derived factor-1-alpha-induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells. Blood 2001; 97:3342-3348.
56. Krystal GW, Honsawek S, Kiewlich D, Liang C, Vasile S, Sun L, McMahon G, Lipson KE. Indoline tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res 2001; 61:3660-3668.
57. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002; 8:620-627.
58. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002; 109:863-867.
59. Stella MC, Comoglio PM. HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 1999; 31:1357-1362.
60. Longati P, Comoglio PM, Bardelli A. Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. Curr Drug Targets 2001; 2:41-55.
61. Atabev N, Gao Y, Yao ZJ, Breckenridge D, Soon L, Soriano JV, Burke TR Jr, Bottaro DP. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem 2001; 276:14308-14314.
62. Gual P, Giordano S, Anguissola S. Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling. Oncogene 2001; 20:156-166.
63. Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C, Sethi T. The presence of a constitutively active phophinositide 3-kinase in small cell lung cancer lines mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 1998; 58:5239-5247.
64. Irani C, Goncharova EA, Hunter DS, Walker CL, Panettieri RA, Krymskaya VP. Phosphatidybnositol 3-kinase but not tuberin required for PDGF-induced cell migration. J Cell Biol 2002; 282: L854-L862.
65. Aznar S, Lacal JC. Rho signals to cell growth and apoptosis. Cancer Lett 2001; 165:1-10.
66. Evers EE, Zondag GCM, Malliri A, Price LS, Ten Klooster JP, van der Kammen RA, Collard JG. Rho family proteins in cell adhesion and cell migration. Eur J Cancer 2000; 36:1269-1274.
67. Bockholt SM, Burridge K. Cell spreading on extracellular matrix proteins induces tyrosine phosphorylation of tensin. J Biol Chem 1993; 268:14565-14567.
68. Salgia R, Avraham S, Pisick E, Li JL, Raja S, Greenfield EA, Sattler M, Avraham H, Griffin JD. The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem 1996; 271:31222-31226.
69. Salgia R, Pisick E, Sattler M, Li JL, Uemura N, Wong WK, Burky SA, Hirai H, Chen LB, Griffin JD. p130Cas forms a signaling complex with adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem 1996; 271:25198-25203.
70. Schaller MD, Otey CA, Hildebrand JD. Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. J Cell Biol 1995; 130:1181-1187.
71. Mah-Becherel MCM, Ceraline J, Deplanque G, Chenard MP, Bergerat JP, Cazenave JP, Klein-Soyer C. Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model. Br J Cancer 2002; 86:803-810.
72. Paris S, Sesboue R, Delpech B, Chauzy C, Thiberville L, Martin JP, Frebourg T, Diarra-Mehrpour M. Inhibition of tumor growth and metastatic spreading by overexpression of inter-alpha-trypsin inhibitor family chains. Int J Cancer 2002; 97:615-620.
73. Spitler LE: Immunotoxins. In: Oldham RK, editor. Principles of Cancer Biotherapy. The Netherlands, Kluwer, 1998.
74. Yano S, Hanibuchi M, Nishioka Y, Nokihara H, Nishimura N, Tsuruo T, Sone S. Combined therapy with anti-p-glycoprotein antibody and macrophage colony-stimulating factor gene transduction for multiorgan metastases of multidrug-resistant human small cell lung cancer in NK cell-depleted scid mice. Int J Cancer 1999; 82:105-111.
75. Maulik G, Madhiwala P, Brooks S, Ma PC, Kijima T, Tibaldi EV, Schaefer E, Parmar K, Salgia R. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med 2002; 6:539-553.
76. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Met Rev 2003; 22:309-325.